PDF(Pubmed)
Abstract：
UNASSIGNED: Primary hepatic sarcomatoid carcinoma (PHSC) is a rare type of malignant tumor in the liver. Nevertheless, few studies have focused on the imaging diagnosis of PHSC. In this study, we collected clinical and computed tomography (CT) imaging data of PHSC from two institutions, aiming to investigate the clinical and radiological characteristics of PHSC.
UNASSIGNED: We retrospectively investigated the clinical characteristics and CT features of 22 PHSC patients (19 males and 3 females; mean age, 63.4 years; range, 49 to 76 years), 95 hepatocellular carcinoma (HCC) patients and 50 intrahepatic cholangiocarcinoma (ICC) patients. Two radiologists independently evaluated the CT features of the three groups. Subsequently, we analyzed the differences in the clinical characteristics and CT features between the PHSC and control groups.
UNASSIGNED: Most PHSCs were larger than 5 cm (72.7%). PHSC mainly showed irregular (81.8%), heterogeneous (100%) masses with ill-defined (72.7%) borders with necrosis (86.4%) on CT, which are more common CT features versus HCC (p < 0.001). In the arterial phase, PHSC always showed noticeable heterogeneous enhancement (100.0%), mainly manifesting as partial arterial phase hyperenhancement (APHE) (86.4%). The enhancement patterns of PHSC mainly included delayed progressive enhancement (72.7%), nonperipheral washout (22.7%), and unclassified enhancement (4.5%), which were significantly different from the HCC enhancement pattern but similar to the enhancement pattern of ICC. In addition, vein tumor thrombus (18.2%), intrahepatic metastasis (27.3%), and lymphadenopathy (27.3%) were relatively common in PHSC. Furthermore, most PHSC tumors classified as LR-M (66.7%) were similar to ICC.
UNASSIGNED: PHSC generally presents as irregularly large masses with necrosis, intrahepatic metastasis, and lymphadenopathy. The CT enhancement of PHSC is mainly part of APHE and delayed progressive enhancement.
UNASSIGNED: We retrospectively investigated the clinical characteristics and CT features of 22 PHSC patients (19 males and 3 females; mean age, 63.4 years; range, 49 to 76 years), 95 hepatocellular carcinoma (HCC) patients and 50 intrahepatic cholangiocarcinoma (ICC) patients. Two radiologists independently evaluated the CT features of the three groups. Subsequently, we analyzed the differences in the clinical characteristics and CT features between the PHSC and control groups.
UNASSIGNED: Most PHSCs were larger than 5 cm (72.7%). PHSC mainly showed irregular (81.8%), heterogeneous (100%) masses with ill-defined (72.7%) borders with necrosis (86.4%) on CT, which are more common CT features versus HCC (p < 0.001). In the arterial phase, PHSC always showed noticeable heterogeneous enhancement (100.0%), mainly manifesting as partial arterial phase hyperenhancement (APHE) (86.4%). The enhancement patterns of PHSC mainly included delayed progressive enhancement (72.7%), nonperipheral washout (22.7%), and unclassified enhancement (4.5%), which were significantly different from the HCC enhancement pattern but similar to the enhancement pattern of ICC. In addition, vein tumor thrombus (18.2%), intrahepatic metastasis (27.3%), and lymphadenopathy (27.3%) were relatively common in PHSC. Furthermore, most PHSC tumors classified as LR-M (66.7%) were similar to ICC.
UNASSIGNED: PHSC generally presents as irregularly large masses with necrosis, intrahepatic metastasis, and lymphadenopathy. The CT enhancement of PHSC is mainly part of APHE and delayed progressive enhancement.
摘要：
UNASSIGNED：原发性肝肉瘤样癌（PHSC）是肝脏中一种罕见的恶性肿瘤。然而，很少有研究集中在PHSC的影像学诊断上。在这项研究中,我们从两个机构收集了PHSC的临床和计算机断层扫描（CT）成像数据，目的探讨PHSC的临床和影像学特点。
UNASSIGNED：我们回顾性调查了22例PHSC患者的临床特征和CT特征（男19例，女3例；平均年龄，63.4年；范围，49至76岁），95例肝细胞癌（HCC）患者和50例肝内胆管癌（ICC）患者。两名放射科医生独立评估了三组的CT特征。随后，我们分析了PHSC与对照组在临床特征和CT表现上的差异.
未经证实：大多数PHSCs大于5cm（72.7%）。PHSC主要表现为不规则（81.8%），CT上具有边界不清（72.7%）的异质性（100%）肿块伴坏死（86.4%），与HCC相比，CT特征更常见（p<0.001）。在动脉期,PHSC总是表现出明显的异质增强(100.0%)，主要表现为部分动脉期增快(APHE)(86.4%)。PHSC的增强模式主要包括延迟渐进增强(72.7%),非外周冲洗（22.7%），和未分类增强(4.5%)，与HCC增强模式有显著差异，但与ICC增强模式相似。此外,静脉肿瘤血栓（18.2%），肝内转移（27.3%），淋巴结病（27.3%）在PHSC中相对常见。此外，大多数分类为LR-M的PHSC肿瘤(66.7%)与ICC相似.
未经证实：PHSC通常表现为不规则的大肿块伴坏死，肝内转移,和淋巴结病。PHSC的CT增强主要是部分APHE和延迟的渐进增强。
UNASSIGNED：我们回顾性调查了22例PHSC患者的临床特征和CT特征（男19例，女3例；平均年龄，63.4年；范围，49至76岁），95例肝细胞癌（HCC）患者和50例肝内胆管癌（ICC）患者。两名放射科医生独立评估了三组的CT特征。随后，我们分析了PHSC与对照组在临床特征和CT表现上的差异.
未经证实：大多数PHSCs大于5cm（72.7%）。PHSC主要表现为不规则（81.8%），CT上具有边界不清（72.7%）的异质性（100%）肿块伴坏死（86.4%），与HCC相比，CT特征更常见（p<0.001）。在动脉期,PHSC总是表现出明显的异质增强(100.0%)，主要表现为部分动脉期增快(APHE)(86.4%)。PHSC的增强模式主要包括延迟渐进增强(72.7%),非外周冲洗（22.7%），和未分类增强(4.5%)，与HCC增强模式有显著差异，但与ICC增强模式相似。此外,静脉肿瘤血栓（18.2%），肝内转移（27.3%），淋巴结病（27.3%）在PHSC中相对常见。此外，大多数分类为LR-M的PHSC肿瘤(66.7%)与ICC相似.
未经证实：PHSC通常表现为不规则的大肿块伴坏死，肝内转移,和淋巴结病。PHSC的CT增强主要是部分APHE和延迟的渐进增强。
